Advertisement
Advertisement
U.S. Markets open in 5 mins
Advertisement
Advertisement
Advertisement
Advertisement

DiaSorin S.p.A. (DIA.MI)

Milan - Milan Delayed Price. Currency in EUR
Add to watchlist
117.15+1.65 (+1.43%)
As of 03:09PM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close115.50
Open114.25
Bid117.15 x 0
Ask117.25 x 0
Day's Range112.50 - 117.35
52 Week Range106.20 - 208.80
Volume75,239
Avg. Volume164,182
Market Cap6.411B
Beta (5Y Monthly)0.11
PE Ratio (TTM)20.37
EPS (TTM)5.75
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & Yield1.00 (0.84%)
Ex-Dividend DateMay 24, 2021
1y Target Est147.50
  • PR Newswire

    BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA. The poster will be presented by Dr. Kim Thacker, Senior Vice

  • PR Newswire

    BrainStorm Announces Upcoming Scientific Conference Presentations

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022. New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (May 4 to 7 in San Francisco, CA) and at the ISEV 2022 Annual Meeting (May 25 to 29 in Lyon, France). An analysis of CSF biomarkers from the NurOwn® Phase 3 trial will be presented at the ALS Drug Devel

  • PR Newswire

    BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on May 16, 2022.

Advertisement
Advertisement